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Editorial
Therapeutic DNA vaccines are mostly plasmidic constructs
containing a strong promoter that allows in situ transcription and
translation of one or many encoded proteins/antigens to induce
protective cellular and humoral immune responses against different
pathogenic organisms [1–5]. Currently, at least 114 open clinical
studies are recruiting patients for distinct clinical phases using a DNA
vaccine approach.
Different routes like intramuscular, intradermal, intravenous,
intranasal and oral can be used for the delivery of such vaccines. Oral
administration is the most commonly used route to deliver live
bacteria considered safe or "GRAS" (Generally Recognized as Safe), a
state designated in the United States by the Food and Drug
Administration agency [6]. The use of Lactic Acid Bacteria harboring
therapeutic DNA plasmids as protective delivery vehicles targeting
plasmids to the cells offers a key advantage, because they protect the
plasmid against degradation and denaturation by nucleases, besides
acting as adjuvants.
The intestinal mucosa is an attractive target for the delivery of
biologically active molecules, as it regulates the delicate balance
between 1) protection against infections and 2) prevention of
inflammatory or autoimmune diseases [7]. Mucosal route vaccination
strategies are associated with reduced side effects, offer easier
administration, and can reduce the costs of production and
implementation [8]. Furthermore, this route offers to significant
advantages over the parenteral administration, as molecules are
administered locally and have the ability to stimulate immune
responses of the Gut-Associated Lymphoid Tissue, the largest
immunological structure of the body [9]. However, the use of bacteria
in humans is hampered by the susceptibility to the lyophilization
process and bacterial death within the gastrointestinal tract (GIT). In
this context, more efficient means of delivery at the mucosal level for
therapeutic lactic bacteria are being developed [10–12].
Despite the time and effort to improve DNA vaccines efficiency,
only some candidates are being tested for prophylactic and therapeutic
applications in different disease models and showed positive results in
vivo [13–16].
Probiotic bacteria have also been bioengineered to modulate the
immune response. Very encouraging studies using the anti-
inflammatory cytokine interleukin-10 (IL-10), an important regulator
in the context of chronic intestinal inflammation, have not succeeded
in reducing inflammation in humans. Moreover, they require high
levels of IL-10, increasing the cost of production and side effects in the
patients [17–21]. In a different approach, the most likely study using a
genetically modified lactic acid bacteria, Lactococcus lactis producing
human IL-10, aims to increase the mucosal bioavailability of IL-10 for
preventing and treating Crohn’s disease patients in a phase-II clinical
trial. However, this study showed that clinical results were
unsatisfactory and no statistically significant therapeutic effect was
found [22].
Although the majority of genetically engineered bacteria are, for
now, only being used in “proof-of-concept” studies, the development of
a protective matrix is needed for efficiently delivering these bacteria to
their specific site.
The key step to achieve this aim consists in improving technologies
for enhancing protection of bacteria against adverse conditions of the
GIT. Selecting Lactic Acid Bacteria probiotic strains exhibiting the
highest tolerance towards GIT environmental stress might increase in
vivo efficacy. Indeed, the tolerance of bacteria towards digestive
conditions is highly dependent on the strain used [12]. Among the
considerations regarding the choice of bacterial strains, adherence to
epithelial cells and mucus, as well as immunomodulatory properties
are crucial to improve delivery efficiency of biologically active
molecules or antigens [23].
The relevant literature proposes the use of encapsulation techniques
to stabilize bacteria, thereby enhancing their viability during
production, storage, and handling [24]. This can be performed using
different strategies like emulsion, extrusion and recently spray-drying
techniques [25–27]. Moreover, microorganisms have been
immobilized within semipermeable and biocompatible matrices
including food-grade biopolymers like alginate, pectin and cellulose
acetate phthalate or milk proteins. By wrapping bacteria in a protective
matrix, this improves both stability and addressing of active
compounds to specifics sites [28]. There is a variety of protective food-
grade matrices that are commonly used for probiotics within tablets
[29], chewing gum [30-32], sachets [33] and capsules [34]. Innovative
probiotic delivery strategies should also take lessons from traditional
fermented foods. Indeed, fermented milk and cheese [23,35,36] are
highly versatile food products and may confer to dairy bacteria a level
of stress tolerance that’s hard to exceed. Indeed, they constitute a
protective matrix rich in proteins and lipids allowing protection
towards digestive enzymes. Moreover, they trigger sublethal doses of
stress in these bacteria, leading to overexpression of key adaptation
proteins [37], to the accumulation of compatible solutes and thus to
enhanced tolerance acquisition. Designer fermented food products can
thus be developed [35,36] and could constitute versatile delivery
vehicles to target engineered bacteria used for DNA vaccine delivery.
Such innovations open new perspectives for the delivery of
biotherapeutic molecules by Lactic Acid Bacteria with enhanced
efficacy when facing the adverse conditions of the human GIT. They
might have an impact on the consolidation of controlled release of
biotherapeutic molecules, on the delivery site and on the quality of
therapeutic effects.
Journal of Bacteriology and
Parasitology Carmo et al., J Bacteriol Parasitol 2017, 8:1DOI: 10.4172/2155-9597.1000e125
Editorial OMICS International
J Bacteriol Parasitol, an open access journal
ISSN:2155-9597
Volume 8 • Issue 1 • 1000e125
References
1. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, et al. (1990) Direct
gene transfer into mouse muscle in vivo. Science 247: 1465-1468.
2. Chow YH, Chiang BL, Lee YL, Chi WK, Lin WC, et al. (1998)
Development of Th1 and Th2 populations and the nature of immune
responses to hepatitis B virus DNA vaccines can be modulated by
codelivery of various cytokine genes. J Immunol 160: 1320-1329.
3. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, et al. (1993)
Heterologous protection against influenza by injection of DNA encoding
a viral protein. Science 259: 1745-1749.
4. Sato Y, Roman M, Tighe H, Lee D, Corr M, et al. (1996)
Immunostimulatory DNA sequences necessary for effective intradermal
gene immunization. Science 273: 352-354.
5. Klinman DM, Klaschik S, Tross D, Shirota H, Steinhagen F (2010) FDA
guidance on prophylactic DNA vaccines: analysis and recommendations.
Vaccine 28: 2801-2805.
6. Schoen C, Stritzker J, Goebel W, Pilgrim S (2004) Bacteria as DNA
vaccine carriers for genetic immunization. Int J Med Microbiol 294:
319-335.
7. Rottiers P, De Smedt T, Steidler L (2009) Modulation of gut-associated
lymphoid tissue functions with genetically modified Lactococcus lactis.
Int Rev Immunol 28: 465-486.
8. Cortes-Perez NG, Lefèvre F, Corthier G, Adel-Patient K, Langella P, et al.
(2007) Influence of the route of immunization and the nature of the
bacterial vector on immunogenicity of mucosal vaccines based on lactic
acid bacteria. Vaccine 25: 6581-6588.
9. Bolton DL, Song K, Wilson RL, Kozlowski PA, Tomaras GD, et al. (2012)
Comparison of systemic and mucosal vaccination: impact on intravenous
and rectal SIV challenge. Mucosal Immunol 5: 41-52.
10. Huyghebaert N, Vermeire A, Neirynck S, Steidler L, Remaut E, et al.
(2005) Development of an enteric-coated formulation containing freeze-
dried, viable recombinant Lactococcus lactis for the ileal mucosal delivery
of human interleukin-10. Eur J Pharm Biopharm 60: 349-359.
11. Termont S, Vandenbroucke K, Iserentant D, Neirynck S, Steidler L, et al.
(2006) Intracellular accumulation of trehalose protects Lactococcus lactis
from freeze-drying damage and bile toxicity and increases gastric acid
resistance. Appl Environ Microbiol 72: 7694-7700.
12. Rokka S, Rantamäki P (2010) Protecting probiotic bacteria by
microencapsulation: challenges for industrial applications. Eur Food Res
Technol 231: 1-12.
13. MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, et al. (1998)
First human trial of a DNA-based vaccine for treatment of human
immunodeficiency virus type 1 infection: safety and host response. J
Infect Dis 178: 92-100.
14. Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, et al. (2006)
Epidermal DNA vaccine for influenza is immunogenic in humans.
Vaccine 24: 4475-4481.
15. Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, et al. (2008)
A SARS DNA vaccine induces neutralizing antibody and cellular immune
responses in healthy adults in a Phase I clinical trial. Vaccine 26:
6338-6343.
16. Tacket CO, Roy MJ, Widera G, Swain WF, Broome S, et al. (1999) Phase 1
safety and immune response studies of a DNA vaccine encoding hepatitis
B surface antigen delivered by a gene delivery device. Vaccine 17:
2826-2829.
17. Van Deventer SJ, Elson CO, Fedorak RN (1997) Multiple doses of
intravenous interleukin 10 in steroid-refractory Crohn’s disease. Crohn’s
Disease Study Group. Gastroenterology 113: 383-389.
18. Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, et al. (2000)
Recombinant human interleukin 10 in the treatment of patients with mild
to moderately active Crohn’s disease. Gastroenterology 119: 1473–1482.
19. Tilg H, Kaser A, Propst A, Schreiber S, Gregor M, et al. (1998)
Recombinant human interleukin-10 (rHuIL-10) therapy in steroid-
refractory chronic active Crohn’s disease (CACD): Induction of
neopterin, a degradation product of the pteridine pathway regulated by
interferon-gamma. Gastroenterology 114: A1100.
20. Colombel JF, Rutgeerts P, Malchow H, Jacyna M, Nielsen OH, et al.
(2001) Interleukin 10 (Tenovil) in the prevention of postoperative
recurrence of Crohn’s disease. Gut 49: 42-46.
21. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, et al. (2006)
A phase I trial with transgenic bacteria expressing interleukin-10 in
Crohn’s disease. Clin Gastroenterol Hepatol 4: 754-759.
22. Bermúdez-Humarán LG, Kharrat P, Chatel JM, Langella P (2011)
Lactococci and lactobacilli as mucosal delivery vectors for therapeutic
proteins and DNA vaccines. Microb Cell Fact 10 Suppl 1:S4.
23. Uroić K, Novak J, Hynönen U, Pietilä TE, Pavunc AL, et al. (2016) The
role of S-layer in adhesive and immunomodulating properties of
probiotic starter culture Lactobacillus brevis D6 isolated from artisanal
smoked fresh cheese. LWT - Food Sci Technol 69: 623–632.
24. Gbassi GK, Vandamme T (2012) Probiotic Encapsulation Technology:
From Microencapsulation to Release into the Gut. Pharmaceutics 4: 149–
163.
25. Huang S, Cauty C, Dolivet A, Le Loir Y, Chen XD, et al. (2016) Double
use of highly concentrated sweet whey to improve the biomass
production and viability of spray-dried probiotic bacteria. J Funct Foods
23: 453-463.
26. Huang S, Méjean S, Rabah H, Dolivet A, Le Loir Y, et al. (2017) Double
use of concentrated sweet whey for growth and spray drying of
probiotics: Towards maximal viability in pilot scale spray dryer. J Food
Eng 196: 11-17.
27. Huang S, Rabah H, Jardin J, Briard-Bion V, Parayre S, et al. (2016)
Hyperconcentrated Sweet Whey, a New Culture Medium That Enhances
Propionibacterium freudenreichii Stress Tolerance. Appl Environ
Microbiol 82: 4641-4651.
28. De Prisco A, Mauriello G (2016) Probiotication of foods: A focus on
microencapsulation tool. Trends Food Sci Technol 48: 27-39.
29. Klayraung S, Viernstein H, Okonogi S (2009) Development of tablets
containing probiotics: Effects of formulation and processing parameters
on bacterial viability. Int J Pharm 370: 54-60.
30. Caglar E, Kavaloglu SC, Kuscu OO, Sandalli N, Holgerson PL, et al.
(2007) Effect of chewing gums containing xylitol or probiotic bacteria on
salivary mutans streptococci and lactobacilli. Clin Oral Investig 11:
425-429.
31. Cruywagen CW, Jordaan I, Venter L (1996) Effect of Lactobacillus
acidophilus supplementation of milk replacer on preweaning
performance of calves. J Dairy Sci 79: 483-486.
32. Bruno FA, Shah NP (2003) Viability of Two Freeze-dried Strains of
Bifidobacterium and of Commercial Preparations at Various
Temperatures during Prolonged Storage. J Food Sci 68: 2336–2339.
33. Lavermicocca P (2006) Highlights on new food research. Dig Liver Dis 38
Suppl 2: S295-299.
34. Cousin FJ, Jouan-Lanhouet S, Dimanche-Boitrel MT, Corcos L, Jan G
(2012) Milk fermented by Propionibacterium freudenreichii induces
apoptosis of HGT-1 human gastric cancer cells. PloS One 7: e31892.
35. Plé C, Richoux R, Jardin J, Nurdin M, Briard-Bion V, et al. (2015) Single-
strain starter experimental cheese reveals anti-inflammatory effect of
Propionibacterium freudenreichii CIRM BIA 129 in TNBS-colitis model.
J Funct Foods 18: 575-585.
36. Plé C, Breton J, Richoux R, Nurdin M, Deutsch SM, et al. (2016)
Combining selected immunomodulatory Propionibacterium
freudenreichii and Lactobacillus delbrueckii strains: Reverse engineering
development of an anti-inflammatory cheese. Mol Nutr Food Res 60:
935-948.
37. Gagnaire V, Jardin J, Rabah H, Briard-Bion V, Jan G (2015) Emmental
Cheese Environment Enhances Propionibacterium freudenreichii Stress
Tolerance. PloS One 10: e0135780.
 
Citation: Rosa does Carmo FL, Carvalho RD, Jan G, Azevedo V (2017) Therapeutic DNA Vaccines: The Final Step for Success . J Bacteriol
Parasitol 8: e125. doi:10.4172/2155-9597.1000e125
Page 2 of 2
J Bacteriol Parasitol, an open access journal
ISSN:2155-9597
Volume 8 • Issue 1 • 1000e125
